Yüklüyor......
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...
Kaydedildi:
| Yayımlandı: | Biomark Res |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/ https://ncbi.nlm.nih.gov/pubmed/32308981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|